BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23266125)

  • 1. [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):42-58. PubMed ID: 23266125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
    Runkel L; Stacey J
    Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
    Guzman M; Hui-Yuen JS
    Drug Des Devel Ther; 2020; 14():2503-2513. PubMed ID: 32612353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD; Yazdany J; Molta CT
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on belimumab for the management of systemic lupus erythematosus.
    Lutalo PM; D'Cruz DP
    Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
    Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
    J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
    Wiglesworth AK; Ennis KM; Kockler DR
    Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.